Shares of Concord Biotech climbed 2.7% to ₹1,500 after the company announced a 32.8% jump in Q1 net profit to ₹58.5 crore, up from ₹44.05 crore a year earlier. The jump followed a ₹257.4 crore revenue rise of 26.2% and an EBITDA increase to ₹82.4 crore, boosting the margin to 32% from 30.1%.
The board is slated to meet on Wednesday, September 23 to decide on a proposed bonus‑share issue, the first such move for the company. The proposal is pending shareholder approval under the applicable provisions.
Promoter entities own 44.08% of the shares, while public shareholders hold 55.92%. Among public holders, Jhunjhunwala family trusts command 24.09% of the equity, with each Aryavir, Aryaman, and Nishtha trust holding 8.03%. Small retail investors—79,000 accounts capped at ₹2 lakh—contributed 7.03% of the stake at the end of June.
The stock, which debuted in August 2023 at ₹741, has more than doubled to its current level, marking a 12.3% YTD rise despite a 4.5% dip in the past month.
Looking ahead, investors will watch the board's decision on the bonus issue and any guidance on future earnings. The sector’s average Q1 margin sits around 28%, positioning Concord’s 32% margin as a competitive edge. Analysts will also gauge whether the bonus proposal signals a bullish stance for the company’s long‑term valuation.